StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Beyfortus (nirsevimab by Quarter

Beyfortus (nirsevimab — direct product sales) — Emerging Markets YoY CER (%) (%)

QuarterlyAnnual

AstraZeneca Beyfortus (nirsevimab: 0.0% in Q2 2026, unchanged from a year earlier. That is the highest of the 13 quarters on record here.

Latest, Q2 2026
0.0%
Period ended Jun 30, 2026
Change on a year earlier
0.0 pts
0.0% in Q2 2025
History
13 quarters
Since Q2 2023
Sources
13
Documents cited below

Where the Q2 2026 figure comes from

“|| Beyfortus | | 47 | | ( 52 ) | | ( 52 ) | | 38 | | ( 49 ) | | - | | - | | - | | 8 | | ( 66 ) | | ( 67 ) | | 1 | | 34 | | 58”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBeyfortus (nirsevimab — direct product sales) — Emerging Markets YoY CER (%) (%)Year on yearSource
Q2 2026Jun 30, 20260.0%0.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 20260.0%0.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 20250.0%0.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 20250.0%0.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 20250.0%0.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 20250.0%0.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 20240.0%0.0 ptsForm 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 20240.0%0.0 ptsForm 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 20240.0%0.0 ptsForm 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 20240.0%–Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 20230.0%–Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 20230.0%–Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 20230.0%–Form 6-K FY2023Q2 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Beyfortus (nirsevimab (%), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-beyfortus-em-cer-yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.